Biotechnology leads with six stocks (ANNX, SION, PRME, KLRS, CLLS, IKT) recently rated strong buy. Large-cap upgrades for COST (>$387B), AME (>$47B), and SEIC (>$10B) signal broad market confidence. Software (RZLV, DCBO, DOMO) also sees strong buy initiations. Average target upside suggests momentum continues, yet several downgrades to Hold in other sectors warrant caution.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.